SEARCH

SEARCH BY CITATION

References

  • 1
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 43-66.
  • 2
    McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005; 23: 133-141.
  • 3
    Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003; 21: 3127-3132.
  • 4
    Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med. 1998; 338: 1272-1278.
  • 5
    Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005; CD001425.
  • 6
    Negrier S, Perol D, Ravaud A, et al. Medroxyprogesterone, interferon alfa-2a, interleukin-2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer. 2007; 110: 2468-2477.
  • 7
    Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005; 353: 2477-2490.
  • 8
    Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-124.
  • 9
    Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-134.
  • 10
    Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370: 2103-2111.
  • 11
    Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-2281.
  • 12
    Motzer RJ, Escudier B, Oudard S, et al. RAD001 vs. placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter phase III study. J Clin Oncol. 2008; 26S: LBA5026.
  • 13
    Figlin RA, Hutson TE, Tomczak P, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2008; 26S: 5024.
  • 14
    Landewe R, van der Heijde D. Primer: challenges in randomized and observational studies. Nat Clin Pract Rheumatol. 2007; 3: 661-666.
  • 15
    Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005; 23: 5027-5033.
  • 16
    Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007; 110: 543-550.
  • 17
    Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002; 20: 289-296.
  • 18
    Common Drug Review, Canadian Agency for Drugs and Technologies in Health: CEDAC Final Recommendation on Reconsideration and Reasons for Recommendation-Sunitinib, 2007. Available at: http://cadth.ca/media/cdr/complete/cdr_complete_sutent_e_april-26-2007%20.pdf Accessed on July 7, 2008.
  • 19
    Hanlon P: Evidence submitted by Kidney Cancer UK (NICE 90), March 2007 update. Available at: http://www.publications.parliament.uk/pa/cm200607/cmselect/cmhealth/503/503we39.htm Accessed on July 7, 2008.
  • 20
    Warren MA, Venner PM, North SA, et al. Then and now: the effect of tyrosine kinase inhibitors on survival in patients with metastatic renal cell carcinoma in Alberta, Canada. J Clin Oncol. 2008; 26S: 16033.
  • 21
    Heng DY, Chi KN, Murray N, et al. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer (mRCC). Paper presented at: Genitourinary Cancers Symposium; February 14-16, 2008; San Francisco, Calif.
  • 22
    Gore ME, Porta S, Oudard S, et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol. 2007; 25( 18 suppl): 5010.
  • 23
    Porta C, Szcyzylik C, Bracarda S, et al. Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2008; 26S: 5114.
  • 24
    Motzer RJ, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol. 2007; 178: 1883-1887.
  • 25
    Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005; 23: 832-841.